Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates

• click to rate

  Posted by Two Blokes Tue at 11:30 PM - Filed in Stock - 2 views
  
  Fate Therapeutics (FATE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.47 per share a year ago.